TARPLIN, DOWNS & YOUNG, LLC

Lobbying for AMGEN INC

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Apr 20, 2026

Lobbying activity 3

Health Issues

IRA, drug pricing in federal programs, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency

Medicare/Medicaid

Medicare coverage and reimbursement issues, Medicare Part B reimbursement, transparency, prescription drug pricing and access, drug pricing in federal programs

Budget/Appropriations

federal budget issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.